CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions.

Biotech leader CSL has manufacturing centers, sales offices, and locations to serve patients and public health around the globe.

CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency. Through the power of innovation, our vision is to advance science to enhance public health worldwide.

csl 非常重視你的寶貴意見，因為它是我們力臻完美的動力。 任何意見，我們必定第一時間回應。

This is a complete list of all products marketed by CSL Behring worldwide. Not all products are available in every country. Visit the Global Selector to link to a specific country.

CSL is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies.

The independent open source Citation Style Language (CSL) project aims to facilitate scholarly communication by automating the formatting of citations and bibliographies. The primary components of the CSL ecosystem are: The CSL schema and specification, which describe how the XML-based CSL styles and locale files should be written and interpreted

CSL Behring是一家全球生物技術領導者，致力於拯救和改善生活。 我們為罕見和嚴重的疾病製造補救措施。

We have announced our 2025 Half Year Financial Results for the period ending 31 st December 2024. Announcement information was released on Tuesday, 11 th February 2025 (AEDT). Please click here to view full information. The 2025 Half Year Financial Results Webcast was broadcast live on Tuesday, 11 th February 2025 (AEDT).

CSL's Share Price information including includes links to associated ASX announcements.